- Patent Title: Quinazoline based EGFR inhibitors containing a zinc binding moiety
-
Application No.: US12423577Application Date: 2009-04-14
-
Publication No.: US08455506B2Publication Date: 2013-06-04
- Inventor: Changgeng Qian , Xiong Cai , Stephen Gould
- Applicant: Changgeng Qian , Xiong Cai , Stephen Gould
- Applicant Address: US MA Lexington
- Assignee: Curis, Inc.
- Current Assignee: Curis, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: A61K31/517
- IPC: A61K31/517
Abstract:
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (I) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
Public/Granted literature
- US20090209758A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY Public/Granted day:2009-08-20
Information query
IPC分类:
